MK-1092 + lispro

**MK-1092 + lispro** is an experimental combination of MK-1092, a novel insulin receptor partial agonist developed as a basal insulin, and insulin lispro (a rapid-acting insulin analog, branded as Humalog). This combination is being tested primarily for its potential in treating diabetes mellitus (both type 1 and type 2). MK-1092 acts as a partial agonist at the insulin receptor, aiming to provide long-acting basal insulin activity, while insulin lispro provides rapid-acting, prandial glucose control. The two agents are given together (not as a coformulation) in some early-phase clinical studies assessing safety, pharmacokinetics, and glucose clamp effects in people with diabetes mellitus[3].

Brand names

Humalog (for lispro)

Other names

MK-1092 and insulin lisproMK1092 and insulin lisproMK 1092 and insulin lisproMK-1092 + HumalogMK-1092/insulin lispro